Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2014

View Archived Issues

Researchers identify potential antiobesity drug target, describe potent inhibitor

BMS discovers novel isonicotinamides as selective and potent GSK-3 inhibitors

New O-GlcNAcase inhibitors patented by Alectos and Merck & Co

Lonza and BioWa sign cell-line technology licensing agreement with arGEN-X

IntelliCell BioSciences collaborates with the GAIN

BioAtla completes engineering of Telephus' MAb TPH-101

Novogen and CanTx advance experimental drug Trx-1

VaxInnate initiates phase I study of seasonal influenza vaccine VAX-2012Q

TapImmune signs option agreement for peptide epitopes targeting folate receptor alpha

Phase III trial of GSK's MAGE-A3 immunotherapeutic in NSCLC misses first co-primary endpoints

VolitionRx reports data from pilot study of NuQ

NeoGenomics launches two next-generation cancer sequencing tests

Horizon Pharma to acquire Vidara Therapeutics

SYL-933, a potent and selective S1P1 receptor agonist

U.S. and German researchers present new BACE1 inhibitors

Paliperidone palmitate 3-month formulation shows positive efficacy in schizophrenia study

Tetraphase Pharmaceuticals provides update on antibiotic candidate eravacycline

Chinese researchers patent novel DOT1L inhibitors

Pfizer's rLP-2086 receives FDA breakthrough therapy designation

Ryanodex NDA granted priority review by FDA

Mallinckrodt completes acquisition of Cadence Pharmaceuticals

Montana State University discloses new vaccines for brucellosis

Virax offers to acquire Pathway Oncology

Pfizer seeks additional indication approval in Japan for Solu-Medrol

IMP-3 as an independent prognostic biomarker of recurrence in endometrial adenocarcinoma

FDA approves Neuraceq for PET imaging of beta-amyloid neuritic plaque density

AVEO Oncology regains full rights to AV-203

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...